We describe the case of a 38-year-old male patient who had acute myeloid leukemia and developed prolonged neutropenia after induction chemotherapy. He developed thrombotic complications at multiple sites. Thrombophlebitis of the hemorrhoidal plexus became exacerbated and developed into critical cellulitis. Because the patient had no human leukocyte antigen-identical sibling, we considered an alternative donor. Because of the necessity for early neutrophil recovery to resolve the critical infection, we proceeded with allogeneic peripheral blood stem cell transplantation (PBSCT) from a microchimeric haploidentical sibling donor. We infused peripheral blood mononuclear cells directly into the patient without cryopreservation and thawing procedures. We aimed for the contaminating granulocytes to act as a granulocyte transfusion. Actually, the neutrophils increased to 1.6 x 10(9)/L on day 1, when the patient showed a temporary resolution of infection. Engraftment was achieved shortly after neutropenic nadir, and acute graft-versus-host disease (GVHD) has been well controlled. Although the patient experiences extensive chronic GVHD, he has been well as an outpatient with a 90% Karnofsky performance status score. The leukemia has been in complete remission for more than 1 year. These findings suggest the clinical utility of a salvage therapy with allogeneic PBSCT from a microchimeric haploidentical donor to treat refractory leukemia concurrent with life-threatening infection.

Download full-text PDF

Source
http://dx.doi.org/10.1532/IJH97.06168DOI Listing

Publication Analysis

Top Keywords

microchimeric haploidentical
12
stem cell
8
cell transplantation
8
haploidentical sibling
8
acute myeloid
8
myeloid leukemia
8
peripheral blood
8
pbsct microchimeric
8
gvhd well
8
patient
5

Similar Publications

Donor C1 Group KIR-ligand inferiority is linked to increased mortality in haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide.

Cytotherapy

December 2024

Department of Internal Medicine I: Hematology with Stem Cell Transplantation, Hemostaseology and Medical Oncology, Ordensklinikum Linz-Elisabethinen, Linz, Austria; Medical Faculty, Johannes Kepler University, Linz, Austria.

Background Aims: In HLA-identical hematopoietic stem cell transplantation (HSCT), HLA-C1 group killer cell immunoglobulin-like receptor (KIR) ligands have been linked to graft-versus-host disease, whereas C2 homozygosity was associated with increased relapses. The differential impact of the recipients versus the donor's HLA-C KIR ligands cannot be determined in HLA-identical HSCT but may be elucidated in the haploidentical setting, in which HLA-C (including the HLA-C KIR ligand group) mismatching is frequently present.

Methods: We retrospectively investigated the effect of recipient versus donor C1 ligand content on survival and complications in post-transplant cyclophosphamide (PTCy)-based haploidentical HSCT (n = 170).

View Article and Find Full Text PDF

Background Aims: With novel therapies improving prognosis, the complications of multiple myeloma after multi-line treatment, particularly myelosuppression, have become a crucial determinant of long-term outcomes. Non-myeloablative allogeneic hematopoietic stem cell transplantation is a feasible option, but the transplant-related mortality rate remains high. Our study presents a relapsed/refractory multiple myeloma patient with a 9-year disease history.

View Article and Find Full Text PDF

Early Mixed Donor Chimerism is a Strong Negative Prognostic Indicator in Allogeneic Stem Cell Transplant for AML and MDS.

Transplant Cell Ther

November 2024

Department of Oncology, McMaster University, Hamilton, Ontario, Canada; Escarpment Cancer Research Institute, Hamilton Health Sciences / McMaster University, Hamilton, Ontario, Canada; Centre for Discovery in Cancer Research, McMaster University, Hamilton, Ontario, Canada.

Background: Allogeneic bone marrow transplantation remains the most potent curative therapy for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) due to the graft-versus-tumor effect provided by donor cells. Donor chimerism is utilized early after transplantation to evaluate engraftment and to monitor the persistence of donor hematopoiesis.

Objective(s): Literature is conflicting regarding to the prognostic utility of early mixed donor chimerism, chimerism kinetic patterns as well as factors associated with it and we sought to clarify this uncertainty.

View Article and Find Full Text PDF
Article Synopsis
  • * A study of 121 patients with acute myeloblastic (AML) and acute lymphoblastic leukemia (ALL) revealed no significant differences in complete chimerism between haploidentical and HLA-identical transplants, though haploidentical HCT experienced more post-transplant complications.
  • * After two years, overall survival rates were 60.6% for HLA-identical and 46.9% for haploidentical HCT, with measurable residual disease (MRD) at 30 and 100
View Article and Find Full Text PDF
Article Synopsis
  • Graft failure and poor graft function present significant challenges in haploidentical hematopoietic stem cell transplantation, particularly for patients with HLA antibodies, and this study explores the role of unrelated umbilical cord blood stem cells as a potential treatment option.
  • A total of 90 patients were assessed, divided into three groups based on the presence of HLA antibodies and the use of UCB infusion, with all groups achieving similar recovery times for granulocytes post-transplantation.
  • The findings suggest that UCB infusion in HLA antibody-positive patients may lead to better outcomes regarding graft-versus-host disease and overall survival rates compared to those who did not receive UCB support.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!